What question did this study set out to answer?

Hepatic Safety of Ketamine and Esketamine for Treatment-Resistant Depression

View Full Paper

Ask AI

Bookmark

Authors

Historical cohort study assesses liver health during ketamine/esketamine treatment, suggesting no significant risk to liver.

To evaluate the hepatic safety of ketamine and esketamine for treatment-resistant depression during repeated use.
Historical cohort study of adults with treatment-resistant depression receiving IV ketamine or IN esketamine at Mayo Clinic (2017-2024)
Included patients with liver enzyme values within 12 months before and 3 months after treatment
Enzyme trajectories were analyzed using generalized linear-mixed models.
No clinically significant changes in liver enzyme trajectories were noted.
Only 5.9% of patients had elevation ≥2× ULN, attributed to factors other than (es)ketamine.
Current findings indicate no need for routine hepatic monitoring in asymptomatic patients.

Singh et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

View Full Paper

Ask AI

Bookmark

Authors

Historical cohort study assesses liver health during ketamine/esketamine treatment, suggesting no significant risk to liver.

To evaluate the hepatic safety of ketamine and esketamine for treatment-resistant depression during repeated use.
Historical cohort study of adults with treatment-resistant depression receiving IV ketamine or IN esketamine at Mayo Clinic (2017-2024)
Included patients with liver enzyme values within 12 months before and 3 months after treatment
Enzyme trajectories were analyzed using generalized linear-mixed models.
No clinically significant changes in liver enzyme trajectories were noted.
Only 5.9% of patients had elevation ≥2× ULN, attributed to factors other than (es)ketamine.
Current findings indicate no need for routine hepatic monitoring in asymptomatic patients.

Singh et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark